VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
FTH
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
FTHFaeth Therapeutics, Inc.
$9.04$568M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
  1. Home
  2. Financial Ratios

  1. Home
  2. Stocks
  3. FTH
  4. Financial Ratios

Faeth Therapeutics, Inc. (FTH) Financial Ratios

Latest Ratios: P/E Ratio -1.1x · EV/EBITDA N/A · ROE -74.0%. (2018–2025 historical series)

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly

FTH Valuation Multiples

Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Market Cap$234M$13M$12M$19M$46M$161M———
Enterprise Value$226M$6M$6M$13M$36M$156M———
P/E Ratio →-1.11————————
P/S Ratio—————————
P/B Ratio0.610.720.320.300.441.10———
P/FCF—————————
P/OCF—————————

P/E links to full P/E history page with 30-year chart

FTH EV Ratios

Enterprise-value multiples — capital-structure-neutral measures of total business value

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
EV / Revenue—————————
EV / EBITDA—————————
EV / EBIT—————————
EV / FCF—————————

FTH Profitability

Margins and return-on-capital ratios measuring operating efficiency

Margins

Full margin charts and quarterly trend are on the Earnings History page

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Gross Margin—————————
Operating Margin—————————
Net Profit Margin—————————

Return on Capital

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
ROE-74.0%-74.0%-58.4%-40.5%-38.9%-45.3%-126.5%——
ROA-61.8%-61.8%-50.4%-35.4%-35.8%-42.1%-177.5%-1091.6%-704.8%
ROIC-76.6%-76.6%-52.6%-36.6%-31.3%-39.7%———
ROCE-76.1%-76.1%-58.3%-41.6%-38.1%-45.5%-117.2%——

FTH Leverage & Debt

Solvency and debt-coverage ratios — lower is generally safer

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Debt / Equity0.080.080.100.100.080.020.04——
Debt / EBITDA—————————
Net Debt / Equity—-0.39-0.16-0.10-0.09-0.03-1.00——
Net Debt / EBITDA—————————
Debt / FCF—————————
Interest Coverage-657.91-657.91-334.08-256.69-220.86-53.92-10.90-6.42-38.87

Net cash position: cash ($9M) exceeds total debt ($2M)

FTH Liquidity & Efficiency

Short-term solvency ratios and asset-utilisation metrics

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Current Ratio5.065.067.7011.9211.9830.384.160.020.48
Quick Ratio5.065.067.7011.9211.9830.384.160.020.48
Cash Ratio4.984.987.5911.6511.8230.193.440.010.25
Asset Turnover—————————
Inventory Turnover—————————
Days Sales Outstanding—————————

FTH Shareholder Yields

Earnings, FCF, buyback, and dividend yields — total returns to shareholders

Dividends

Full dividend history and growth charts are on the Dividend History page

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Dividend Yield—————————
Payout Ratio—————————

Total Shareholder Return Metrics

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Earnings Yield—————————
FCF Yield—————————
Buyback Yield0.0%0.0%0.0%53.7%0.0%0.0%———
Total Shareholder Yield0.0%0.0%0.0%53.7%0.0%0.0%———
Shares Outstanding—$1M$1M$1M$2M$1M$2M$1M$1M

Key Metrics

Growth RegimeContracting
ProfitabilityNegative
Balance SheetStrained
Cash FlowBurning
Top Statement Risk

Cash burn versus thin liquidity

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q3)

Book-Value Discount Reflects Impaired Earnings

Based on reported figures, FTH trades at 0.61 times book value while carrying a negative trailing P/E of -1.11, a combination that signals the market is pricing the balance sheet rather than any earnings stream it can currently demonstrate.

A sub-1.0 price-to-book multiple against a deeply negative earnings base suggests investors are discounting reported equity of roughly $167.9M, likely because the accumulated deficit of -$489.8M and recurring cash burn cast doubt on how much of that book value can be converted into shareholder returns. Forward earnings and EV-based multiples are unavailable, so the valuation cannot be benchmarked against own history or growth expectations. Relative to peers such as IMVT and CRVS, which trade at much higher price-to-book multiples, FTH's discount appears to reflect a weaker perceived capacity to monetize its asset base, though this inference warrants further investigation as peer earnings profiles differ materially.

Leverage Minimal, Coverage Metrics Meaningless

According to reported figures, FTH's debt-to-equity ratio fell to 0.00 by 2026Q3 as total debt declined from $5.0M to $145.0K, but interest coverage remains deeply negative, so debt service capacity cannot be meaningfully measured.

Near-zero leverage removes debt covenants and refinancing as a near-term pressure point, which is a constructive feature for a pre-profit company. However, interest coverage has been negative across the series, reaching -1571.33 in 2025Q4, which reflects an absence of operating earnings rather than a debt-service burden and therefore offers little insight into solvency. The more relevant risk is equity-funded survival, since leverage is low but operating losses continue to erode the capital base. Investors should monitor how the remaining cash reserve is depleted relative to ongoing burn rather than rely on debt ratios.

Current Ratio Overstates Practical Liquidity

As reported in financial statements, FTH's current ratio of 16.12 in 2026Q3 appears strong, yet cash of $14.2M set against a $170.2M net loss in 2026Q1 suggests the headline liquidity figure may overstate the practical runway available.

The current ratio has been volatile, moving from 5.06 in 2025Q4 to 19.69 in 2026Q2 and 16.12 in 2026Q3, and such swings likely reflect the timing of capital raises rather than a stable operating liquidity profile. Because quarterly cash burn appears to run in the range of several million dollars in operating outflows, a high current ratio on a small cash base implies limited buffer against continued losses. Under severe stress, the position would depend on whether equity markets remain open for further raises, a dependency that the reported figures alone cannot confirm.

Working Capital Metrics Lack Operating Substance

Based on reported figures, FTH's receivable, inventory, and payable cycle metrics are largely unavailable, with only sporadic DPO and asset turnover readings, so the cash conversion cycle cannot be assessed with confidence.

The absence of consistent DSO, DIO, and CCC data is consistent with a pre-commercial oncology business that has no meaningful revenue or inventory base, so working capital efficiency is not a relevant lens for this company at present. Sporadic payable readings, such as DPO of 13,895 days in 2026Q3, are not economically interpretable and likely reflect minimal operating activity rather than supplier leverage. Analysts should not infer supplier or customer dynamics from these figures and should instead focus on the cash runway.

Misapplied Current Ratio Obscures Cash Runway

The current ratio is the metric most commonly misapplied to a pre-revenue biotech like FTH, and according to reported balance sheet data its 16.12 reading in 2026Q3 may obscure a thin cash base relative to quarterly burn.

A high current ratio is often read as evidence of solvency, but for a clinical-stage company its numerator is dominated by cash that is being consumed by R&D and stock-compensation-heavy SG&A, so the ratio reflects timing of financing rather than operating strength. A more useful lens is months of cash runway, calculated as cash on hand divided by average quarterly operating cash outflow, combined with the trajectory of equity raises. Stock-based compensation rising to $12.9M in 2026Q1 further suggests that reported cash burn may understate economic cost, which warrants further investigation.

Download Financial Ratios Data

Includes 30+ ratios · 8 years · Updated daily

Consensus & Technical Research Suite
Open FTH Terminal

FTH Chart Terminal

WASM

Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.

Launch Terminal

Live Breakouts Feed

LIVE

High-probability breakout stocks crossing their pivot across 5 pattern engines.

Explore Setups

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

10-year return with dividends reinvested.

Calculate

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

FTH — Frequently Asked Questions

Quick answers to the most common questions about buying FTH stock.

What is Faeth Therapeutics, Inc.'s P/E ratio?

Faeth Therapeutics, Inc.'s current P/E ratio is -1.1x. This places it at the 50th percentile of its historical range.

What is Faeth Therapeutics, Inc.'s ROE?

Faeth Therapeutics, Inc.'s return on equity (ROE) is -74.0%. The historical average is -63.9%.

Is FTH stock overvalued?

Based on historical data, Faeth Therapeutics, Inc. is trading at a P/E of -1.1x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.